The global amyloidosis treatment market size was valued at USD 5.99 billion in 2025 and is projected to grow from USD 6.42 billion in 2026 to USD 11.23 billion by 2034, registering a CAGR of 7.23% during the forecast period (2026-2034). North America dominated the amyloidosis treatment market with a share of 39.42% in 2025.
Amyloidosis treatment involves therapies designed to reduce the production or accumulation of abnormal amyloid fibrids that deposit in tissues and organs, disrupting their normal function. Amyloidosis treatments are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The amyloidosis treatment market demand is driven by improved disease recognition, advances in diagnostic methods, and the development of therapies targeting specific amyloid-producing mechanisms. Healthcare providers use gene silencing therapies and monoclonal antibodies to control abnormal protein production, contributing to amyloidosis treatment market growth.
Download a Free Sample To learn more about this report,
Shift toward Precision Medicine for Amyloidosis Treatment
The amyloidosis treatment market analysis shows a shift toward precision medicine based on amyloid type, genetic profile, and affected organs. Diagnostic testing helps healthcare providers distinguish between AL and ATTR amyloidosis and select appropriate therapies for individual patients.
Growth of TTR Stabilizer Therapies for Transthyretin Amyloidosis (ATTR)
Use of transthyretin (TTR) stabilizer therapies is shaping the amyloidosis treatment market by helping prevent the breakdown of TTR proteins and the formation of amyloid deposits. These therapies are used to manage transthyretin amyloidosis, particularly cases involving cardiomyopathy or hereditary polyneuropathy. This development is expanding treatment options and supporting disease management for eligible patients.
Supply chain disruptions are expected to have a high impact on the amyloidosis treatment market share due to dependence on specialized medicines, active pharmaceutical ingredients, and biologic drug materials. The market is expected to follow a stair-step recovery, as shortages of specialized therapies, manufacturing delays, and cold chain transportation disruptions can affect treatment availability. The market is expected to grow at a CAGR of 7.23%, but supply chain constraints could lower this by 1.0 percentage point, resulting in a growth of around 6.23%. As supply conditions normalize, the amyloidosis treatment market growth is expected to gradually return to 7.23%.
The amyloidosis treatment market forecasts strategic investment activity driven by development of antibody-based therapies and research into amyloid deposit removal. In March 2026, Immutrin raised USD 87 million in Series A funding to advance its antibody-based therapy for transthyretin amyloidosis (ATTR), with the goal of removing existing amyloid deposits and progressing its lead candidate through clinical proof of concept.
Expansion of Novel Therapies for Transthyretin Amyloidosis and Demand for Treatments for Amyloid-Related Cardiomyopathy Drives Market
Development of novel therapies for transthyretin amyloidosis is supporting market growth by expanding treatment options for patients with hereditary and wild-type forms of the disease. Advances in transthyretin stabilizers and gene-silencing therapies help address the underlying causes of the condition by reducing abnormal protein accumulation or limiting protein production. Continued advances in targeted therapy are strengthening demand within the amyloidosis treatment market.
Demand for treatments for amyloid-related cardiomyopathy is driving market growth as improved diagnostic methods help identify more patients with heart damage caused by amyloid deposits. Cardiac imaging, biomarker testing, and greater awareness of disease symptoms are helping distinguish this condition from other forms of heart disease.
Risk of Adverse Effects from Treatment and High Cost of Amyloidosis Treatment Restraints Market Expansion
Risk of adverse effects from treatment can create challenges in managing amyloidosis. Certain therapies may cause side effects that require dose adjustments, additional monitoring, or changes in treatment plans. These risks can be more difficult to manage in patients with existing organ damage, potentially complicating care and limiting the suitability of some therapies.High cost of amyloidosis treatment can limit patient access to advanced therapies. Treatment expenses may include specialized medications, diagnostic testing, hospital care, and long-term monitoring. Limited insurance coverage and affordability concerns may delay treatment or restrict access to newer therapies.
Expansion of Companion Diagnostics for Amyloidosis Drugs and Development of Biomarker-Guided Treatment Selection Open New Avenues for Market Players
Expansion of companion diagnostics offers growth opportunities for diagnostic developers, pharmaceutical companies, and clinical laboratories supporting amyloidosis treatment. Tests that help identify amyloidosis subtypes, distinguish light-chain (AL) from transthyretin (ATTR) amyloidosis, and assess treatment eligibility support more targeted therapy selection and strengthen collaboration between diagnostic and drug developers.
Development of biomarker-guided treatment selection offers growth opportunities for pharmaceutical companies, diagnostic developers, and clinical laboratories by enabling more individualized amyloidosis management. Tests measuring markers such as NT-proBNP, cardiac troponin, and serum free light chains can help assess organ involvement, characterize disease status, and monitor treatment response, supporting more informed therapeutic decisions and the development of targeted treatment strategies.
Chemotherapy led the treatment segment with a share of 34.6%, supported by its use in treating certain forms of amyloidosis, particularly light-chain (AL) amyloidosis, where therapy targets the abnormal plasma cells producing amyloid-forming proteins.
Supportive care is projected to register a CAGR of 8.26% during the forecast period, fueled by the need to manage organ complications and maintain quality of life in patients with amyloidosis. Measures such as managing fluid retention, addressing cardiac symptoms, and supporting kidney function complement disease-directed treatment and ongoing clinical monitoring.
Request Customizationto receive a tailored report.
Hospitals and clinics accounted for a 67.4% share of the end-user segment, reflecting their role in diagnosing amyloidosis and monitoring complications affecting the heart, kidneys, and other organs. Access to multidisciplinary specialists and advanced diagnostic services supports the management of complex cases.
The home care settings segment is estimated to witness a CAGR of 8.72% during the forecast period, driven by the demand for ongoing symptom management and follow-up care outside hospital facilities.
Speak to an Analystto discuss market opportunities.
The North America amyloidosis treatment market accounted for a dominant share of 39.42% in 2025.
U.S. market benefits by the FDA’s traditional approval of daratumumab and hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain (AL) amyloidosis. The decision was based on clinical trial results showing improvements in major organ deterioration, progression-free survival, and overall survival compared with the treatment regimen without daratumumab.
Canada’s market is supported by the availability of specialized assessment and treatment pathways for cardiac amyloidosis, including transthyretin amyloid cardiomyopathy (ATTR-CM). Health Canada has approved vutrisiran for adults with wild-type or hereditary ATTR amyloidosis with cardiomyopathy. These developments highlight the role of disease-specific therapies, cardiac assessment, and ongoing monitoring in amyloidosis care.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific amyloidosis treatment market is expected to achieve a growth rate of 9.11% during the forecast period, making it the fastest-growing region.
China's First List of Rare Diseases, published by the National Health Commission and other government departments, includes hereditary transthyretin amyloidosis. This supports greater recognition of the condition within the healthcare system, leading to treatment focus across healthcare systems.
Designated Intractable Disease program in Japan includes systemic amyloidosis and provides eligible patients with access to financial assistance for qualifying medical expenses. This framework helps address the long-term treatment burden associated with amyloidosis and supports the need for specialized care.
Ministry of Health and Family Welfare also highlighted early diagnosis, innovation, and stronger collaboration as priorities for rare-disease management, reinforcing the importance of improving specialist diagnostic and treatment pathways. For instance, The Amrita Amyloid Centre in Kochi brings together specialists across these disciplines and offers advanced diagnostic capabilities, including cardiac imaging, tissue biopsy, mass spectrometry-based amyloid typing, and genetic testing for transthyretin variants
The Europe amyloidosis treatment market is anticipated to record a growth rate of 6.74% during the forecast period.
National Amyloidosis Centre in London offers a specialized service that provides assessment, treatment, and follow-up for patients with amyloidosis and related disorders. The UK’s National Institute for Health and Care Excellence (NICE) also provides guidance on specialized treatments such as patisiran for hereditary transthyretin amyloidosis.
Amyloidosis Center at Heidelberg University Hospital brings together specialists in hematology, cardiology, nephrology, and neurology to diagnose and treat different forms of amyloidosis. The center provides individualized treatment plans, including chemotherapy and stem cell transplantation for light chain amyloidosis, along with therapies for other disease types.
Latin American amyloidosis treatment market is estimated to grow at a CAGR of 7.41% during the forecast period. Brazil’s Ministry of Health’s Clinical Protocol and Therapeutic Guidelines for Transthyretin Amyloidosis establishes criteria for diagnosis, treatment, patient eligibility, and follow-up through the public healthcare system.
Mexican Position Statement for the Diagnosis and Treatment of Cardiac Amyloidosis also provides a diagnostic algorithm combining cardiac imaging and laboratory tests. It emphasizes early recognition of warning signs and individualized treatment based on disease subtype and comorbidities.
The Middle East & Africa amyloidosis treatment market is projected to grow at a CAGR of 7.16% during the forecast period. UAE's Cleveland Clinic Abu Dhabi, which operates a dedicated Multiple Myeloma and Amyloidosis Program. The program brings together hematologists, cardiologists, nephrologists, and other specialists to diagnose and manage amyloidosis and related plasma cell disorders.
The Amyloidosis Africa initiative, which includes South African cardiology expertise, promotes clinician training, awareness, and improved diagnostic pathways for cardiac amyloidosis across the continent.
The amyloidosis treatment market competitive landscape is highly fragmented, with established pharmaceutical companies, biotechnology firms, and specialized developers of therapies for rare diseases. Key players such as Pfizer, Alnylam Pharmaceuticals Ionis Pharmaceuticals, AstraZeneca, and BridgeBio Pharma are estimated to account for 35–40% of the global amyloidosis treatment market share.
Established players compete mainly through transthyretin stabilizers, RNA interference therapies, and antisense oligonucleotides. Emerging and regional players in the amyloidosis treatment market ecosystem focus on novel therapeutic approaches, disease-specific therapies, and solutions targeting underlying amyloid protein production.
August 2026: Attralus received U.S. FDA Fast Track designation for zamubafusp alfa (AT-02), its investigational pan-amyloid depleter, for the treatment of light-chain (AL) amyloidosis.
May 2026: AstraZeneca reported Phase III CARES program results for anselamimab, an investigational anti-amyloid fibril therapy for AL amyloidosis.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Bone Metastasis Market Size, Share, Growth, Analysis, Report, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Alzheimer’s Therapeutics Market Size, Share, Growth, Analysis, 2034
Cardiometabolic Disease Market Size, Share, Growth, Analysis, 2034
Antiviral Drugs Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com